-
2023-508290-81-00
5
2020-12-18
Immunoglobulin G4-related disease (IgG4-RD)
-
2023-504959-27-00
5
2020-12-09
Participants with Limited Stage-Small Cell Lung Cancer, who have recei
-
2024-514468-26-00
9
2020-12-04
Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), O
-
2024-513296-41-00
4
2020-12-03
Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2024-516481-11-00
5
2020-09-22
Metastatic Castration-Resistant Prostate Cancer
-
2024-512501-76-00
10
2020-07-28
Hemophilia
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-503628-22-00
5
2020-07-16
Lupus Nephritis (LN)
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer
-
2024-516532-97-00
9
2020-03-26
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2022-502844-11-00
5
2020-01-29
severe to moderately severe hemophilia B (FIX:C ≤ 2%)
-
2023-510248-19-00
5
2020-01-21
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
-
2024-515156-21-00
5
2020-01-09
Ulcerative Colitis
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2023-506832-33-00
5
2019-11-06
haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
-
2023-509276-42-00
6
2019-10-30
Children and Adolescents with Cancers Harboring V600 mutation.